Mesenchymal Stromal Cell EVs via ECM Protein Culture
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for obtaining extracellular vesicles (EVs) from mesenchymal stromal cells (MSCs) do not consistently produce biologically active EVs, which limits their therapeutic effectiveness in treating medical conditions such as inflammatory diseases and ischemic heart disease, and there is a need for improved EVs that can rescue organ functionality and ECM composition.
Innovation Solution
Culturing MSCs in the presence of polypeptides containing a laminin α5 or α4 chain, or the extracellular domain of human MCAM, to produce EVs that are biologically active and exhibit stronger therapeutic effects than EVs from standard cultures, including improved organ rescue and ECM composition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MSCs are cultured under standard conditions to obtain EVs, then the production process is simple and easy to manufacture, but the EVs produced have weak or partial biological activity and limited therapeutic effectiveness
Solution Approach 1:
The patent changes the biochemical parameters of the culture system by introducing specific ECM proteins (laminin-521, laminin-421) and growth factors (bFGF, TGF-β1) to transform standard culture conditions into a more physiologically relevant environment. This parameter change induces MSCs to produce EVs with enhanced biological activity and therapeutic effectiveness.
Solution Approach 2:
The patent uses ECM proteins as intermediary substances that mediate between the culture system and the MSCs. These intermediaries (laminin, bFGF, TGF-β1) create a more natural microenvironment that signals to the cells to produce biologically active EVs, bridging the gap between simple culture conditions and complex physiological states.
2Reliability
If MSCs are used for therapy, then regenerative and immunomodulatory effects are achieved, but storage and logistical problems arise requiring ultralow temperature storage and pre-processing equipment
Solution Approach 1:
The patent extracts the therapeutic function from the living MSCs themselves and transfers it to their secreted products (EVs and conditioned medium). By taking out the active therapeutic components and separating them from the living cell infrastructure, the therapy can be stored and transported without requiring ultralow temperature facilities or pre-processing equipment, while maintaining regenerative and immunomodulatory effects.
Solution Approach 2:
The patent creates a functional copy of MSC therapy using EVs and conditioned medium that replicate the regenerative and immunomodulatory effects of living MSCs. This copy can be stored at standard freezer temperatures and administered without the complex logistics required for living cell therapy, making the treatment more accessible while preserving therapeutic effectiveness.
3Reliability
If EVs are produced without specific ECM proteins to simplify the process, then manufacturing is easier, but the EVs fail to rescue organ functionality and improve ECM composition
Solution Approach 1:
The patent applies preliminary action by pre-coating the culture surface with specific ECM proteins (laminin-521, laminin-421) before introducing the MSCs. This preliminary preparation of the culture environment programs the cells to produce EVs enriched with ECM proteins and enhanced biological activity, enabling them to rescue organ functionality and improve ECM composition in diseased tissues.
Data Source
AI summary
The present invention relates to methods for obtaining extracellular vesicles (EVs) from cells such as mesenchymal stromal cells (MSCs), wherein the cells are cultured in the presence of polypeptides from the extracellular matrix proteins laminin alpha-5, laminin alpha-4 or their functional fragments, or in the presence of polypeptides comprising the extracellular domain of human MCAM protein. The invention further relates to EVs obtained by the above methods. The EVs are useful in the treatment and prophylaxis of medical conditions such as inflammatory diseases, ischemic heart disease and acute respiratory distress syndrome.